Episurf Medical Yönetim

Yönetim kriter kontrolleri 3/4

Episurf Medical CEO'su Pal Ryfors, Jun2017 tarihinde atandı, in görev süresi 7.42 yıldır. in toplam yıllık tazminatı SEK 4.50M olup, şirket hissesi ve opsiyonları dahil olmak üzere 84.4% maaş ve 15.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.92% ine doğrudan sahiptir ve bu hisseler SEK 1.78M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 8.5 yıldır.

Anahtar bilgiler

Pal Ryfors

İcra Kurulu Başkanı

SEK 4.5m

Toplam tazminat

CEO maaş yüzdesi	84.4%
CEO görev süresi	7.4yrs
CEO sahipliği	1.9%
Yönetim ortalama görev süresi	6.4yrs
Yönetim Kurulu ortalama görev süresi	8.5yrs

Son yönetim güncellemeleri

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Apr 03

Recent updates

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Apr 03

We Think Some Shareholders May Hesitate To Increase Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation

May 03

CEO Tazminat Analizi

Pal Ryfors'un ücretlendirmesi Episurf Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 80m
Jun 30 2024	n/a	n/a	-SEK 85m
Mar 31 2024	n/a	n/a	-SEK 92m
Dec 31 2023	SEK 5m	SEK 4m	-SEK 95m
Sep 30 2023	n/a	n/a	-SEK 97m
Jun 30 2023	n/a	n/a	-SEK 94m
Mar 31 2023	n/a	n/a	-SEK 84m
Dec 31 2022	SEK 5m	SEK 4m	-SEK 77m
Sep 30 2022	n/a	n/a	-SEK 72m
Jun 30 2022	n/a	n/a	-SEK 71m
Mar 31 2022	n/a	n/a	-SEK 69m
Dec 31 2021	SEK 4m	SEK 3m	-SEK 69m
Sep 30 2021	n/a	n/a	-SEK 67m
Jun 30 2021	n/a	n/a	-SEK 66m
Mar 31 2021	n/a	n/a	-SEK 63m
Dec 31 2020	SEK 4m	SEK 3m	-SEK 64m
Sep 30 2020	n/a	n/a	-SEK 66m
Jun 30 2020	n/a	n/a	-SEK 69m
Mar 31 2020	n/a	n/a	-SEK 73m
Dec 31 2019	SEK 2m	SEK 2m	-SEK 70m
Sep 30 2019	n/a	n/a	-SEK 66m
Jun 30 2019	n/a	n/a	-SEK 62m
Mar 31 2019	n/a	n/a	-SEK 59m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 58m
Sep 30 2018	n/a	n/a	-SEK 58m
Jun 30 2018	n/a	n/a	-SEK 59m
Mar 31 2018	n/a	n/a	-SEK 55m
Dec 31 2017	SEK 2m	SEK 1m	-SEK 61m

Tazminat ve Piyasa: Pal 'nin toplam tazminatı ($USD 419.58K ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 243.31K ).

Tazminat ve Kazançlar: Pal 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Pal Ryfors (41 yo)

7.4yrs

Görev süresi

SEK 4,500,000

Tazminat

Mr. Pal Ryfors is Independent Director of Vivesto AB since May 2022. He serves as Chief Executive Officer of Episurf Medical AB (publ) since June 2, 2017 and served as its Acting Sales Director since 2021....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Pal Ryfors	Chief Executive Officer	7.4yrs	SEK 4.50m	1.92% SEK 1.8m
Veronica Wallin	Chief Financial Officer	7.4yrs	Veri yok	0.049% SEK 45.7k
Katarina Flodström	Chief Operating Officer	5.4yrs	Veri yok	0.016% SEK 14.6k
Fredrik Zetterberg	Marketing Director	7.8yrs	Veri yok	0.0041% SEK 3.8k
Ylva Bonde	Head of QA & RA	less than a year	Veri yok	Veri yok
Patrick Jamnik	President of Episurf Medical Inc	3.3yrs	Veri yok	0.041% SEK 38.1k

6.4yrs

Ortalama Görev Süresi

43yo

Ortalama Yaş

Deneyimli Yönetim: EPIS B 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ulf Grunander	Independent Chairman of the Board	3.5yrs	SEK 400.00k	0.058% SEK 54.1k
Annette Rampe	Independent Director	3.5yrs	SEK 200.00k	0.037% SEK 34.1k
Laura Shunk	Independent Director	7.8yrs	SEK 200.00k	0.12% SEK 113.6k
Leif Ryd	Member of Clinical Advisory Board & Director	15.8yrs	SEK 800.00k	0.090% SEK 82.9k
Tim Spalding	Member of Clinical Advisory Board	9yrs	Veri yok	Veri yok
Johannes Holz	Member of Clinical Advisory Board	9yrs	Veri yok	Veri yok
Mats Brittberg	Member of Clinical Advisory Board	9yrs	Veri yok	Veri yok
Karl Eriksson	Member of Clinical Advisory Board	9yrs	Veri yok	Veri yok
Christian Krueger	Independent Director	8.5yrs	SEK 200.00k	0.046% SEK 42.6k
Adam Mitchell	Member of Clinical Advisory Board	7.8yrs	Veri yok	Veri yok
C. van Dijk	Member of Clinical Advisory Board	5.6yrs	Veri yok	Veri yok
Joao Mendes	Member of Clinical Advisory Board	no data	Veri yok	Veri yok

8.5yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EPIS B 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

Episurf Medical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Executive Officer recently bought kr2.3m worth of stock

Independent Director recently bought kr129k worth of stock

Insufficient new directors

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024

Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024

Recent updates

Consensus revenue estimates increase by 850%, EPS downgraded

Episurf Medical AB (publ) to Report Fiscal Year 2024 Results on Mar 06, 2025

Third quarter 2024 earnings released: kr0.024 loss per share (vs kr0.078 loss in 3Q 2023)

Episurf Medical AB (publ) to Report Q2, 2025 Results on Jul 11, 2025

Chief Executive Officer recently bought kr2.3m worth of stock

New major risk - Market cap size

Consensus revenue estimates decrease by 22%, EPS upgraded

Second quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 2Q 2023)

New major risk - Shareholder dilution

Episurf Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 90.158983 million.

Independent Director recently bought kr129k worth of stock

Insufficient new directors

Consensus EPS estimates fall by 14%

First quarter 2024 earnings released: kr0.077 loss per share (vs kr0.087 loss in 1Q 2023)

New major risk - Market cap size

Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now

Full year 2023 earnings: EPS and revenues miss analyst expectations

Here's Why Episurf Medical (STO:EPIS B) Must Use Its Cash Wisely

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Episurf Medical AB (Publ) Receives Four Additional Patent Approval Notification

Is Episurf Medical (STO:EPIS B) In A Good Position To Invest In Growth?

Consensus revenue estimates decrease by 19%

Price target decreased by 27% to kr4.00

Third quarter 2023 earnings released

Episurf Medical AB (publ), Annual General Meeting, Apr 09, 2024

Episurf Medical Announces 510(k) Submission for Big Toe Implant

Episurf Members Announces Nomination Committee for Episurf Medical's Annual General Meeting in 2024

Episurf Medical Announces Early Clinical Results from Episealer Talus Study Presented at Scientific Congress

Episurf Medical Announces Prospective Episealer Talus Clinical Study

Episurf Medical AB (publ) Announces First Commercial Case in the US Has Been Scheduled for Surgery

Second quarter 2023 earnings released

Chief Executive Officer recently bought kr660k worth of stock

Will Episurf Medical (STO:EPIS B) Spend Its Cash Wisely?

First quarter 2023 earnings released

Chief Executive Officer recently bought kr72k worth of stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

Episurf Medical AB (publ), Annual General Meeting, May 04, 2023

Episurf Medical AB (publ) Announces Dennis Stripe Not Stand for Re-Election as Chairman of the Board of Directors

Episurf Medical AB (Publ) Receives Notice of Allowance from the United States Patent and Trademark Office

Episurf Medical AB (publ) Receives FDA 510(k) clearance for Episealer® Patellofemoral System

Consensus revenue estimates fall by 20%

Third quarter 2022 earnings released

Price target decreased to kr5.65

Episurf Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 09, 2024

Episurf Medical Announces That the Episealer® Knee Technology and Clinical Results

Episurf Medical AB (Publ) Appoints Nomination Committee

We're Not Very Worried About Episurf Medical's (STO:EPIS B) Cash Burn Rate

Episurf Medical AB (Publ) Provides Update on 510(K) Application to FDA for the Episealer Patellofemoral System

Episurf Medical Announces New U.S. Patent Approval for Episurf Medical

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong for Episurf Medical

Episurf Medical Announces Results from Study with Episealer® Knee Implant Accepted for Presentation at Swedish Orthopaedic Congress

Consensus forecasts updated

Episurf Medical AB (Publ) Announces New Patent Approval in Hong Kong

Second quarter 2022 earnings released

Episurf Medical AB (Publ) Announces First Surgery in India with the Knee Implant Episealer® Has Been Scheduled

First quarter 2022 earnings: Revenues miss analyst expectations

Price target decreased to kr5.65

Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System

New European Patent Approves for Episurf Medical

Episurf Medical AB (Publ) Announces the Initiation of a Prospective Investigator-Initiated Study with 2 Years Follow-Up of 25 Episealer Talus Patients

First Indian Patent Approval for Episurf Medical

Episurf Medical Receives Reimbursement Coverage for Episealer Talus in Belgium

Episurf Medical AB’s Implants Receive National Regulatory Approval in Hong Kong

Consensus revenue estimates fall by 34%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

The European Patent Office Approves European Patent for Episurf Medical

the European Patent Office EPO Announces Its Intention to Grant Another European Patent for Episurf Medical AB (publ)